Long-Term Response Rates to Infliximab Therapy for Crohn’s Disease in an Outpatient Cohort

BACKGROUND: Infliximab’s efficacy in the induction and maintenance of remission in luminal Crohn’s disease has been confirmed by randomized, controlled trials. Less clearly described are long-term outcomes in the clinical practice setting since the establishment of regularly scheduled, every eight-w...

Full description

Saved in:
Bibliographic Details
Main Authors: Christopher W Teshima, Adrienne Thompson, LeRose Dhanoa, Levinus A Dieleman, Richard N Fedorak
Format: Article
Language:English
Published: Wiley 2009-01-01
Series:Canadian Journal of Gastroenterology
Online Access:http://dx.doi.org/10.1155/2009/180840
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND: Infliximab’s efficacy in the induction and maintenance of remission in luminal Crohn’s disease has been confirmed by randomized, controlled trials. Less clearly described are long-term outcomes in the clinical practice setting since the establishment of regularly scheduled, every eight-week maintenance infliximab infusions. Existing reports describing clinical practice outcomes are limited by short durations of follow-up or by the use of episodic dosing, or focus on safety data rather than clinical outcomes.
ISSN:0835-7900